kesimpta 20 mg/0.4 ml rastvor za injekciju u napunjenom penu
novartis ba d.o.o. - ofatumumab - rastvor za injekciju u napunjenom penu - 20 mg/0.4 ml - 1 napunjeni pen sadrži 20 mg ofatumumaba u 0,4 ml rastvora za injekciju (50 mg/ml)
tysabri
biogen netherlands b.v. - natalizumab - multipla skleroza - selektivni imunosupresivi - tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: , patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 i 5. 1), , or, patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.
tysabri 300 mg/15 ml koncentrat za rastvor za infuziju
medis international d.o.o. sarajevo - natalizumab - koncentrat za rastvor za infuziju - 300 mg/15 ml - 1 bočica sa 15 ml koncetrata za rastvor za infuziju sadrži: 300 mg natalizumaba
ponvory
janssen-cilag international n.v. - ponesimod - multipla skleroza, Рецидивно-Ремиттирующее - imunosupresivi - ponvory is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (rms) with active disease defined by clinical or imaging features.
tyruko
sandoz gmbh - natalizumab - multiple sclerosis, relapsing-remitting; multiple sclerosis - imunosupresivi - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 i 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.
olumiant
eli lilly nederland b.v. - baricitinib - artritis, reumatoidni - imunosupresivi - rheumatoid arthritisbaricitinib is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (dmards). olumiant se može koristiti kao monoterapija ili u kombinaciji s metotreksatom. atopic dermatitisolumiant is indicated for the treatment of moderate to severe atopic dermatitis in adult and paediatric patients 2 years of age and older who are candidates for systemic therapy. alopecia areatabaricitinib is indicated for the treatment of severe alopecia areata in adult patients (see section 5. juvenile idiopathic arthritisbaricitinib is indicated for the treatment of active juvenile idiopathic arthritis in patients 2 years of age and older who have had an inadequate response or intolerance to one or more prior conventional synthetic or biologic dmards:- polyarticular juvenile idiopathic arthritis (polyarticular rheumatoid factor positive [rf+] or negative [rf-], extended oligoarticular),- enthesitis related arthritis, and- juvenile psoriatic arthritis. baricitinib may be used as monotherapy or in combination with methotrexate.
zeposia
bristol-myers squibb pharma eeig - ozanimod hidroklorid - multiple sclerosis, relapsing-remitting; colitis, ulcerative - imunosupresivi - multiple sclerosiszeposia is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (rrms) with active disease as defined by clinical or imaging features. ulcerative colitiszeposia is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.
livercol 20 mg/1 tableta film tableta
tuzlafarm d.o.o. tuzla - rosuvastatin - film tableta - 20 mg/1 tableta - 1 film tableta sadrži: 20 mg rosuvastatina (u obliku rosuvastatin kalcijuma)
livercol 10 mg/1 tableta film tableta
tuzlafarm d.o.o. tuzla - rosuvastatin - film tableta - 10 mg/1 tableta - 1 film tableta sadrži: 10 mg rosuvastatina (u obliku rosuvastatin kalcijuma)
mavenclad 10 mg/1 tableta tableta
glosarij cd d.o.o. sarajevo - kladribin - tableta - 10 mg/1 tableta - 1 tableta sadrži: 10 mg kladribina